Feng Gang, Ma Hui-Min, Huang Hou-Bao, Li Ya-Wei, Zhang Peng, Huang Jian-Jun, Cheng Long, Li Guo-Rong
Clinical Laboratory, The First Affiliated Hospital of Wannan Medical College, Wuhu 241001, Anhui, China,
Anhui Province Key Laboratory of Active Biological Macro-molecules Research, Wannan Medical College, Wuhu 241002, Anhui, China,
Cancer Manag Res. 2019 Feb 7;11:1263-1274. doi: 10.2147/CMAR.S188216. eCollection 2019.
COL5A1 has been identified to be involved in metastasis of clear cell renal cell carcinoma (ccRCC) by bioinformatic analysis. This study aimed to investigate COL5A1 expression and its clinical significance in ccRCC. The function of COL5A1 in ccRCC was further investigated.
COL5A1 expression was examined in 256 ccRCC tissues and paired adjacent normal renal tissues by immunohistochemistry and real-time quantitative PCR. The clinical significance of COL5A1 expression was evaluated. Downregulation of COL5A1 was achieved using siRNA. The effects of COL5A1 silencing on cell proliferation, apoptosis, migration, invasion in vitro, and tumor growth in vivo were investigated.
COL5A1 expression was upregulated in the majority of the ccRCC tissues at both protein and mRNA levels. COL5A1 expression was significantly correlated with tumor diameter, tumor stage, tumor grade, distant metastasis, recurrence, necrosis, and sarcomatoid (all <0.05). COL5A1 expression was also significantly associated with overall survival of ccRCC patients (HR 1.876; =0.027) and recurrence-free survival of localized ccRCC patients (HR 4.751; <0.001). The accuracy of TNM, University of California Los Angeles Integrated Staging System, and Mayo clinic stage, size, grade, and necrosis prognostic models was improved when COL5A1 expression was added.
COL5A1 knockdown significantly inhibited cell proliferation, induced cell apoptosis, inhibited cell migration and invasion in vitro, and inhibited tumor growth in vivo. Therefore, COL5A1 may be a novel prognostic biomarker and a promising therapeutic target for ccRCC.
通过生物信息学分析已确定COL5A1参与透明细胞肾细胞癌(ccRCC)的转移。本研究旨在探讨COL5A1在ccRCC中的表达及其临床意义。进一步研究了COL5A1在ccRCC中的功能。
采用免疫组织化学和实时定量PCR检测256例ccRCC组织及配对的癌旁正常肾组织中COL5A1的表达。评估COL5A1表达的临床意义。使用小干扰RNA(siRNA)实现COL5A1的下调。研究COL5A1沉默对体外细胞增殖、凋亡、迁移、侵袭及体内肿瘤生长的影响。
在大多数ccRCC组织中,COL5A1在蛋白质和mRNA水平均上调。COL5A1表达与肿瘤直径、肿瘤分期、肿瘤分级、远处转移、复发、坏死和肉瘤样变显著相关(均P<0.05)。COL5A1表达还与ccRCC患者的总生存期(HR 1.876;P=0.027)和局限性ccRCC患者的无复发生存期显著相关(HR 4.751;P<0.001)。当加入COL5A1表达时,TNM、加利福尼亚大学洛杉矶分校综合分期系统以及梅奥诊所分期、大小、分级和坏死预后模型的准确性得到提高。
COL5A1基因敲低显著抑制细胞增殖,诱导细胞凋亡,抑制体外细胞迁移和侵袭,并抑制体内肿瘤生长。因此,COL5A1可能是ccRCC一种新的预后生物标志物和有前景的治疗靶点。